In this study, using KRAS(G12D) or PIK3CA(H1047R), two mutations derived from GBM patients, we demonstrated that activation of the RAS/PI3K pathway promotes tumorigenesis and necrosis formation. The gene discussed is KRAS; the disease is glioblastoma.